Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
The COVID-19 pandemic has severely affected adolescents. Safe and effective vaccines are pivotal tools in controlling this pandemic. We reviewed the safety profile of the BNT162b2 COVID-19 vaccine in adolescents using mostly real-world data to assist decision-making. We used random-effects model met...
Main Authors: | Patrick D. M. C. Katoto, Amanda S. Brand, Liliane N. Byamungu, Jacques L. Tamuzi, Tamirirashe C. Mahwire, Marcel K. Kitenge, Charles S. Wiysonge, Glenda Gray |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-11-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2022.2144039 |
Similar Items
-
Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: A systematic review and meta-analysis
by: Patrick DMC. Katoto, et al.
Published: (2023-01-01) -
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses
by: Patrick DMC Katoto, et al.
Published: (2023-12-01) -
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-12-01) -
Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01) -
Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021-12-01)